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Cancer progression is a multistep process during which normal cells exhibit molecular changes that culminate into the highly
malignant and metastatic phenotype, observed in cancerous tissues. The initiation of cell transformation is generally associated
with genetic alterations in normal cells that lead to the loss of intercellular- and/or extracellular-matrix- (ECM-) mediated
cell adhesion. Transformed cells undergo rapid multiplication and generate more modiﬁcations in adhesion and motility-
related molecules which allow them to escape from the original site and acquire invasive characteristics. Integrins, which are
multifunctional adhesion receptors, and are present, on normal as well as transformed cells, assist the cells undergoing tumor
progression in creating the appropriate environment for their survival, growth, and invasion. In this paper, we have brieﬂy
discussed the role of ECM proteins and integrins during cancer progression and described some unique conditions where
adhesion-related changes could induce genetic mutations in anchorage-independent tumor model systems.
1.Introduction
Cancer aﬄicts an organ or a tissue by inducing abnormal
and uncontrolled division of cells that either constitute it or
migrate to it. At the cellular level, this is caused by genetic
alterations in networks that regulate cell division and cell
death.Theincreasedrateofproliferationoftransformedcells
causes further mutations in genes that regulate other cellular
processes. For example, transformed cells eventually gain the
capacity to invade into other tissues by modulating their
own kinetic properties without losing the capacity to divide
rapidly and avoid cell death, despite internal and external
perturbations.
Cancer cells adopt diverse mechanisms to cope with
the various physiological insults, such as low oxygen and
metabolic stress, that they encounter [1]. These mechanisms
have been discussed in a recent review [2], and based upon
that discussion, six important hall marks of cancer cells can
be identiﬁed. These are (a) sustained proliferative signalling,
(b) evasion of growth suppressors, (c) resistance to cell
death, (d) replicative immortality, (e) copious angiogenesis,
and (f) active invasion and metastasis. In addition to these,
cancer cells can exhibit two other properties, that is, tumor
promoting inﬂammation and gene instability that assist
the cells in the transition from normal to oncogenic phe-
notype [2]. Eventually transformed cells undergo somatic
evolution and generate diverse populations that tend to
harbor genetic and epigenetic instabilities and alterations
[3]. These changes also assist the cells in adapting to
the variations in the surrounding microenvironment and
even to alter it. As a consequence of these alterations, the
tumor milieu or microenvironment becomes an “enabling
element”fordeﬁningsomecharacteristicsofcancercells.For
example, the tumor microenvironment can induce cancer
cells in acquiring anoikis resistance and in selecting new
sites to colonize and grow. Sometimes these cells remain
unresponsive until signals generated from the ECM reach
the cell’s nucleus and they determine whether the cell would
proceed to the next stage in cancer progression or not. This
response of cancer cells to ECM-generated signals similar
to the “dynamic reciprocity” proposed by Bisell for normal
cells. An example of such an adaptation of cancer cells to
their microenvironment and the resultant clonal selection of
invasive cells has been recently reported [4–6].2 International Journal of Cell Biology
Metastatic invasion is generally the ﬁnal phase of cancer
progression, and it involves formation of new blood vessels
eitherbyneovasculogenesis,inwhichendothelialcellprecur-
sors (angioblasts) migrate to the tumor site and diﬀerentiate
and assemble into primitive blood vessels, or by angiogenesis
in which we observe sprouting of new blood vessels from
preexisting ones, or their longitudinal bifurcation, in the
tumor [7]. The invasive tumor cells migrate through these
newly formed blood vessels to other sites such as lung and
liver brain and this leads to the death of tumor-bearing
patients or animals as the case may be.
Based on available evidence, the entire process of cancer
formationcanbedividedintofourdiﬀerentstages:initiation,
progression, epithelial mesenchymal transition (EMT), and
metastasis (see Figure 1). At the initiation stage, a normal
cell acquires oncogenic properties mainly through genetic
alterations, which lead to changes in cell structure, adhesion
properties, and response to signals from ECM proteins. In
the second stage, transformed cells respond to cues from the
altered environmental conditions and acquire properties of
adhesion-independent growth and colonization. The third
stage is also referred to as a transitional or the EMT stage,
and, in this stage, the fully transformed cells begin to exhibit
mesenchymal gene expression patterns which induce them
to invade into the neighbouring tissue and enter into blood
circulation [8]. The fourth and prominent stage is metastasis
in which the invasive mesenchymes like cells move from
the primary site and colonize in a new location. This stage
spreads the disease into diﬀerent parts of the body and
involvesseveralalterationsintheadhesionpropertiesofcells.
From all earlier observations, it is clear that the cell
adhesion in transformed cells plays an important role in
all four stages of cancer formation. This paper highlights
recent studies done on the integrin-mediated interaction of
transformed cells with the ECM and discusses its role in
cancer progression.
2. ECM Components and Properties
Overthepasttwodecades,researchintheﬁeldofcancerbiol-
ogy has focussed extensively on the role of ECM constituents
during cancer progression. These molecules comprise the
cell’s microenvironment, and they can aﬀect the mechanical
and biophysical properties of cells as well as that of the ECM
such as its mechanics, geometry, and topology [9].
In some tissues, mainly of epithelial origin, ECM
constituents are present in the basement membrane that
deﬁnes the boundaries of that tissue. In this location, the
organization of these components is diﬀerent than in the
matrix. In the basement membrane, we notice molecules
such as collagens, proteoglycans, laminins, and ﬁbronectins
associate strongly with certain carbohydrate polymers and
generate a membrane-like structure which facilitates the
formation of a framework of cells and ECM constituents
[10]. Speciﬁc domains in ECM proteins that are created
by partial gene duplication and exon shuﬄing during the
process of evolution [11] play a critical role in keeping the
cells attached to the ECM and the basement membrane and
initiating signalling cascades in the cells.
Inside the cells, the ECM-induced signaling pathways
are transmitted mainly through integrin molecules that are
transmembrane multifunctional ECM receptors. Integrin-
mediated signaling in association with many cofactors, for
example, cytokines, growth factors, and intracellular adapter
molecules, can signiﬁcantly aﬀect diverse cell processes such
as cell cycle progression, migration, and diﬀerentiation. The
interplay between the biophysical properties of the cell and
ECM establishes a dynamic, mechanical reciprocity between
the cell and the ECM in which the cell’s ability to exert
contractilestressesagainsttheextracellularenvironmentbal-
ances the elastic resistance of the ECM to that deformation
[4, 9]. The ECM in association with the available growth
factors activates a sequence of reactions with a complex
network of proteases, sulfatases, and possibly other enzymes
to liberate and activate various signalling pathways in a
highly speciﬁc and localized fashion. The maintenance of
ECM homeostasis therefore involves a tight balance between
biosynthesis of ECM proteins, their 3D organization, cross-
linking, and degradation.
3. Modulation of ECM-Generated
SignalinginCancer
During cancer progression, we observe signiﬁcant changes
in the structural and mechanical properties of ECM con-
stituents. It has been reported that changes in matrix
stiﬀness, which oﬀers resistance to cell traction forces
[12] and also inﬂuences “shape dependence” in cells, can
contribute actively to the tumor formation [13]. Dereg-
ulation of cell shape and alterations in the interactions
with the ECM are considered as important hallmarks of
cancer cells. These changes in ECM homeostasis can be
brought about by the properties of tumor cells themselves
or by the secretions of other surrounding cells such as
ﬁbroblasts, macrophages, and leukocytes [14]. Integrin ECM
interactions are signiﬁcantly modulated by crosstalk with
several other signal-generating molecules, some of them are
receptor molecules on the cell surface whereas others are
present in the cytoplasm as adaptor proteins and actin-
binding proteins [15]. These signaling crosstalks in which
integrin molecules lie at the center are very useful for
the transition of transformed cells to metastatic cells [16].
Integrin-generatedECMremodellingisfurthercontrolledby
the localization and activity of proteases [17]. One example
of such an integrin-directed cancer progression is seen
in breast cancers, where adhesion-independent mammary
epithelial cells secrete laminin-5 and luminal cells secrete
laminin-1. This leads to aberrant polarity in cells, causing
upregulation of metalloproteinases (MMPs, such as MMP9)
and induction of tumor invasion and metastasis [18–20].
4.Integrins:ItsLigandsandSignalling
Integrins are heterodimeric cell-surface receptors that medi-
ate adhesion to ECM and immunoglobulin superfam-
ily molecules. At least 24 distinct integrin heterodimers
are formed by the combination of 18 α-subunits andInternational Journal of Cell Biology 3
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Figure 1: Various steps in tumor initiation and progression where panel (a) represents initiation of tumor by transforming normal cells,
panel (b) shows the modulation of ECM proteins allowing transformed cells to multiply, panel (c) shows progression of cancer by replacing
normal cells, panel (d) represents the invasion, where cancer cells migrate into the blood stream by modulating ECM and cell adhesion
molecules, and panels (e) shows metastasis where the cancer cells are localized at diﬀerent sites enabling angiogenesis.
8 β-subunits. Speciﬁc integrin heterodimers preferentially
bind to distinct ECM proteins like laminin, collagen IV,
ﬁbronectin, and so forth. The level of integrin expression
on the cell surface dictates the eﬃciency of cell adhesion
and migration on diﬀerent matrices. While some integrins
selectively recognise primarily a single ECM protein ligand
(e.g., α5β1 recognises primarily ﬁbronectin), others can
bind several ligands (e.g., integrin αvβ3 binds vitronectin,
ﬁbronectin, ﬁbrinogen, denatured or proteolysed collagen,
and other matrix proteins). Several integrins recognise the
tripeptide Arg-Gly-Asp (e.g., αvβ3, α5β1, αIIbβ3), whereas
others recognise alternative short peptide sequences (e.g.,
integrin α4β1 recognises EILDV and REDV in alternatively
spliced CS-1 ﬁbronectin). Inhibitors of integrin function
include function-blocking monoclonal antibodies, peptide
antagonists, and small molecule peptide mimetics matrix
[21–23].
The positioning of integrin receptors acts as a direct
bridge between the extracellular matrix and the internal
cell cytoskeleton by transducing key intracellular signals
by associating with the clusters of kinases and adaptor
proteins in focal adhesion complexes. Integrins thus act as
mediators in transmitting diﬀerent signals from “inside out”
(intracellular to extracellular) and “outside in” (extracellular
to intracellular) between ECM to cells and vice versa.
Through these pathways, ECM proteins are able to control
proapoptotic and antiapoptotic cascades by regulating the
activity of caspase 8 and caspase 3 [24–26]. ECM-integrin
interactions thus determine the balance of apoptotic and cell
survival signals and maintain the homeostasis of organs and
tissues. Although integrins lack kinase activity, by inter- and
intramolecular clustering, they recruit and activate kinases,
such as focal adhesion kinases (FAKs) and src family kinases
(sFKs)toafocaladhesioncomplex.Inadditiontoscaﬀolding
molecules,suchasp130CRK-associatedsubstrate(p130CAs;
also known as BCAR1), integrins also couple the ECM
to actin cytoskeleton by recruiting cytoskeletal proteins,
including talin, paxillin, α-actinin, tensin, and vinculin.
Additionally, they form a ternary complex consisting of an
integrin-linked kinase, PINCH, and parvin to regulate many
scaﬀolding and signalling functions required for integrin-
mediated eﬀects on cell migration and survival [27].
5.IntegrinExpressionandSignallingin
Cancer Progression
Although anchorage-independent growth is a hallmark of
malignant transformation, integrins expression levels and
activity are an important role in diﬀerent steps of tumour4 International Journal of Cell Biology
progression including initiation [28]. Higher expression
of α3, α5, α6, αv, β1, β4, α6β4, α9β1, αvβ5, and αvβ3
integrins is directly correlated with the progression of the
disease [10]. Several epithelial cell tumors showed the altered
α6β4, α6β1, αvβ5, α2β1, and α3β1 integrin expression [29].
Integrin recruitment to membrane microdomains has been
shown to be regulated by tetraspanins and crucially regulate
integrin function in tumour cells [30]. Recent studies have
demonstratedthatcellsignallinggeneratedbygrowthfactors
and oncogenes in transformed cells requires collaboration
with speciﬁc integrins, especially during tumour initiation.
In tumor cells, several survival signals are upregulated upon
integrinligation,whichincludesincreasedexpressionofBCl-
2orFlIP(alsoknownasCFlAR),activationofthePI3K-AKT
pathway or nuclear factor-κB( n F - κB) signaling, and/or p53
inactivation [24].
Invasive cancer cells evacuate from the primary site and
migratetothesecondary sitebytheprocessoftissueinvasion
and cell migration. Integrin-mediated pathways involving
focal adhesion kinase (FAK) and src family kinase (SFK)
signaling play a major role in this. In order to survive in
the new location and to withstand the stressful conditions of
hypoxia, nutrient deprivation, and inﬂammatory mediators
the migratory cells increase the blood supply to themselves
by neoangiogenesis. This is achieved by increased expression
of αvβ3a n dαvβ5 integrins and by deposition of provisional
matrix proteins such as vitronectin, ﬁbrinogen, von Wille-
brand factor, osteopontin, and ﬁbronectin in the tumour
microenvironment. Interaction between these molecules
plays a critical role in the process of generating new blood
vessels in the newly formed tumor site [31, 32].
Integrins found on tumour-associated normal cells,
such as the vascular endothelium, perivascular cells, ﬁbrob-
lasts, bone-marrow-derived cells, and platelets, also have a
profound eﬀect in tumor progression via integrin-mediated
pathways. A summary of these has been given in Table 1 [33–
47].
6. GeneticandChromosomal Aberrationsat
the Onset of Cancer
Neoplasia occurs when cells are exposed to cancer-
promoting substances that cause single or multiple prema-
lignant genetic/epigenetic changes which may coalesce to
form a large lesion. These genetic changes may have neutral,
deleterious, or advantageous eﬀects on the proliferation of
a clone or clones of cells. Neutral or deleterious genetic
changes may result in stagnation or cell death, whereas
the cell receiving advantageous events may result in higher
proliferation, recruitment of blood vessels to the developing
tumors,andgaintheabilitytometastasize[48].Themodelof
Braakhuis et al., 2004 [49], advanced this idea by suggesting
that initial genetic alterations occur in stem cells, forming
a patch and expanding ﬁeld of cells with the original
and subsequent genomic and or chromosomal alterations.
Then, clonal selection of one or more cells within this
ﬁeld of preneoplastic cells leads to the development of a
carcinoma. There is a considerable cytogenetic variability
among cells reﬂecting heterogeneity due to clonal evolution
within the original tumor [50]. Initial heterogeneity or cell-
to-cell diﬀerences in cancer are due to cytoskeletal alter-
ations which result in defecting chromosomal segregation
and lead to karyotypic variations during mitosis, causing
chromosomal aberrations, for example, NUMA1 gene at
11q13, which results in multipolar spindles, leading to
daughter cells that diﬀer from each other and their mother
cells [51]. Structural chromosome alterations also occur
due to deletions, translocations, isochromosomes, dicentric
chromosomes, and endoduplicated chromosomes. The gain
or ampliﬁcation of chromosomal segments is driven by more
than one gene [52]. Structural rearrangements involving the
cleavage and fusion of centromeres from participating chro-
mosomes, also referred to as Robertsonian translocations,
are the most frequently observed alterations. Chromosomal
aberrations identiﬁed with the help of cytogenetic methods
including FISH, cCGH, or aCGH showed the gain of the
entire long arm of chromosome 3 which ampliﬁes the
EGFR gene in SCCHN [53], 8q24 gain to amplify MYC and
PTK2 in primary tumors, 11q13 ampliﬁcations to amplify
cyclin D1 gene, loss of 3q14 causes deletion of fragile site
FRA3B/FHIT, necessary to protect cells from accumulation
of DNA damage [48]. Aberrations mainly in chromosome
13 and also involving chromosomes 6, 11, 12, and 17 are
associated with B-CLL [54].
7. Anchorage-Independent Tumor
Model System
The wide range of in vivo tumor models like syngeneic,
human tumor xenograft, orthotopic, metastatic, and genet-
ically engineered mouse models is available from the basis
of the compounds selected and treatments that go into
clinical testing of patients [55]. The ability to exhibit
anchorage-independent cell growth (colony-forming capac-
ity in semisolid media) has been considered to be funda-
mental in cancer biology because it has been connected with
tumor cell aggressiveness in vivo such as tumorigenic and
metastatic potentials and also utilized as a marker for in
vitro transformation. Although multiple genetic factors for
anchorage-independencehavebeenidentiﬁed,themolecular
basis for this capacity is still largely unknown [56, 57].
During the process of in vitro tumorigenesis, various onco-
genes with distinct pathways have been shown to transform
anchorage-dependent cells to anchorage-independent cells
[5, 57]. For example, transfer of c-Myc (a transcription
factor), v-Src (a tyrosine kinase), or H-Ras (a small
GTPase)intospontaneouslyimmortalizedmouseembryonic
ﬁbroblasts (MEFs) provides the cells an ability to grow in
an anchorage-independent manner [56, 57]. Anchorage-
independent multicellular spheroids made by Ewing tumor
cell lines were more closely related to primary tumors with
respect to cell morphology, cell-cell junctions, proliferative
index, and kinase activation [58].
However, changes in ECM and cell adhesion molecular
interaction and genetic variations were observed till the
date only with the primary or secondary tumors. We haveInternational Journal of Cell Biology 5
Table 1: Various integrins in association with diﬀerent ligands to induce diﬀerent signaling pathways in generation of tumor and metastasis.
Integrin type Interacting ECM protein Activated signaling cascade Tumor/metastasis Reference
α3β1 Laminin
MMP9 and oncogenic Ras,
VEGF, FAK-paxillin signaling
cascade
Invasion in keratinocytes,
Induces angiogenesis,
Human hepatoma cells
[33, 34]
α6β1 Laminin Urokinase plasminogen activator
and MMP-2, PI3Kinase, Src
Tumor invasion in pancreatic
cells [35, 36]
α7β1 Laminin Rho-A signaling cascade Invasion in breast cancer [37]
α2β1, α1β1, α10β1,
αIIβ1 Collagen FAK and src signaling
Invasion of melanoma cells,
cancer progression, and invasion
of lung adenocarcinoma
[38, 39]
αvβ1, αvβ6, αvβ3 Vitronectin, syndican,
thromospondin-1
MMP9, urokinase signaling,
MEK/Erk/NF-κB, PKCa, FAK
Metastatic breast Cancer,
pancreatic, cervical, colon,
lung/liver metastasis
[40–42]
α9β1 CCN3, osteopontin Src, P130 Cas, Rac, NOS
signaling Metastatic potential [43]
αIIb3, αvb3 Von Willebrand factor
Interacts with
thrombospondin-1 and induces
VEGF/FGF signaling
Breast cancer [44, 45]
α5 Fibronectin FAK, ERK, PI-3K, ILK, and
nuclear factor-kappa B -
Metastatic lung and cervical
cancer [46, 47]
αLβ2 Intercellular cell adhesion
molecules Breast cancer [1]
developed a cellular model system by using normal, adherent
rat ﬁbroblast cell lines. These cells lose their cytoskeletal
organization and speciﬁcity to ﬁbronectin as α5β1 integrins
are constantly recycled between cytoplasm and plasma. In
the drastic unfavorable stressful conditions, the mechanical,
phenotypic, and genetic characteristics are altered/modiﬁed
to sustain their identity [5, 26]. We observed that this cellular
model system represents a tumor with all characteristics
of cancer described by Hanahan and Weinberg 2011 as
hallmarks of cancer.
The cells during the nonadhesion process can evade
from cell death by caspase 3 interaction with unligated α5β1
integrins inducing resistance to integrin-mediated death
(IMD) and also gain the ability to metastatise. Mutational
changes mainly with 2;6 Robertsonian’s translocation and
activated Ras, FAK, and PKC provide self-suﬃcient growth
signals potential for uncontrollable growth of the cells
(Figure 2). Upregulated Spp1, MMP3, Egfr, Rb1, Ddit3,
Egln3, Vegfa, Stc1, Hif1a, MMP3, and altered pathways
like glycolysis/gluconeogenesis and hypoxia (Pfkm, HK2,
Pdk1, Adh1, aldh3a1, and Slc2a) lead the cells to invade,
metastasize, and sustain angiogenesis. We observed another
phenomenon of dediﬀerentiation by gaining the stem-cell-
like and multidrug resistance properties by expressing Cd133
and ABCG-2 when the cells are exposed to unfavorable
condition [5].
The anchorage-independent cellular model system rep-
resents a multicentric tumor model system apprehended
with genes related to tumor progression, angiogenesis, and
metastasis (Figure 2). It is very advantageous, convenient,
and possible model system to study the eﬀect of various
cancer-mediated drugs at the initial stage itself for the proper
diagnosis.
8.IntegrinSignallingasaTarget in
Cancer Treatment
Several studies showed the correlation of integrin inhibition
at any point of its action will lead to the inhibition of
tumor progression [24]. Therefore, integrins are focused
pharmacologicallyinthetreatmentandpreventionofcancer.
Antagonists of these integrins suppress cell migration and
invasion of primary and transformed cells by inducing
apoptosis in primary cells could block tumor angiogenesis
and metastasis. Recycling integrins present on the surface of
endothelial cells are targeted in the blood stream by exposing
to the circulating drugs and agents [59]. Various antibod-
ies, cyclic peptides, disintegrins, and peptidomimetics are
meant to bind the targeted integrins to prevent integrin
ligation. cRGD, cyclic arginine-glycine-aspartic acid; RGDK,
arginine-glycine-aspartic acid-lysine; TRAIL, tumour necro-
sis factor-related apoptosis-inducing ligand are being used
as antagonists integrins to hit the integrin ligand function.
The function of upregulated αvβ3 integrin can be blocked by
function-blocking monoclonal antibodies, such as LM 609
[60]. The human αv integrin speciﬁc monoclonal antibody
CnTo 95, which targets both αvβ3a n dαvβ5 integrins
to induce endothelial apoptosis, also had antitumour and
antiangiogenic eﬀects in xenograft tumour models [15].
Cilengitide, inhibitor of both αvβ3a n dαvβ5 integrins
and volociximab, a function-blocking monoclonal antibody
against integrin α5β1, inhibits angiogenesis and impedes
tumour growth [61, 62]. αvβ3 is targeted by various ther-
apeutic antibodies like LM609, vitaxin, humanized mouse
monoclonal derived from LM609, CNTO 95, humanized
IgG1, c7E3, chimeric mouse human, 17E6, mouse mono-
clonalantibodiestoinhibittumourgrowth,andangiogenesis6 International Journal of Cell Biology
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Figure 2: This ﬁgure shows the hallmark characteristics of transformed cells at initial stages.
in tumour xenografts and preclinical studies [63]. The
prognostic α5β1 integrins in ovarian cancer can be targeted
eﬀectively both in vitro and in vivo by using speciﬁc antibod-
ies.Cell-mediatedα5β1adhesioncanbeblockedwithasmall
molecule antagonist (SJ479), a ﬁbronectin-derived peptides
in prostate, and colon cancer models [64, 65]. Recent activity
isextendedtodetecttumorsandangiogenesisanddeliverthe
drugs to the site of cancer by coupling integrin antagonists to
a paramagnetic contrast agent or radionuclide in rabbit and
mouse tumour models [66, 67].
9. Conclusion
Normal cells lead to the transformation when exposed to
adverse conditions such as anchorage independence and
eﬀects are found to be similar to the eﬀect of carcinogens
and mutagens. These cells could alter the ECM and other cell
adhesion molecules by showing altered integrins expression
on their surface and are associated with diﬀerent kinds of
growth factors and oncogene. ECM-integrin interactions
along with other growth factors provide the diversiﬁed
anchorage-independent signals to the transformed cells to
progress as cancers, metastasis, and angiogenesis. Several
tumours are sustained with diversiﬁed integrins found to
be speciﬁc to the tumour-host microenvironment. In future,
these integrins can be targeted at the initial stages of cancer
by using integrin antagonists to minimize the growth of
tumour and metastasis.
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